Project description
Novel saturated benzene bioisosteres developed
Modern medicinal chemistry exploits only a limited chemical space, with most drugs that target proteins consisting of phenyl-containing organic molecules. Although safe compounds can be identified outside conventional drug chemistry, the chemical synthesis methodology for delivering novel compounds is limited. The EU-funded BENOVELTY project will synthesise novel saturated bioisosteres of benzene rings. Scientists will incorporate these structures into known anti-inflammatory, antiviral and antihypertensive drugs instead of the fragment of the benzene ring. The key objective is to expand the drug chemical space and generate patent-free analogues with improved physicochemical and biological properties.
Objective
More than 500 of all existing drugs are phenyl-containing organic molecules. During the recent years, however, pharmaceutical companies struggle to deliver novel drugs to the market, because of the lack of innovative practical approaches towards novel drug-like “chemical space.” In this project, we will address this issue by developing novel saturated bioisosteres for ortho- and meta-substituted benzenes, and incorporate them into several known drugs (intiinflamatory Aceclofenac, antiviral Tipranavir, antihypertensive Oxprenolol, etc) to provide novel patent-free analogues with improved physico-chemical and biological properties.
Fields of science
Programme(s)
Funding Scheme
ERC-COG - Consolidator GrantHost institution
02094 KYIV
Ukraine
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.